Thermo Fisher Scientific Inc. $TMO Shares Sold by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 84.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,669 shares of the medical research company’s stock after selling 14,076 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Thermo Fisher Scientific were worth $1,338,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in TMO. Assetmark Inc. boosted its stake in Thermo Fisher Scientific by 22.9% in the 4th quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock worth $21,819,000 after purchasing an additional 7,023 shares during the period. North Dakota State Investment Board acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $7,505,000. Boston Trust Walden Corp grew its holdings in shares of Thermo Fisher Scientific by 9.7% during the fourth quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company’s stock valued at $25,480,000 after buying an additional 3,873 shares in the last quarter. Xponance LLC lifted its stake in Thermo Fisher Scientific by 8.1% in the 4th quarter. Xponance LLC now owns 59,295 shares of the medical research company’s stock worth $34,358,000 after acquiring an additional 4,436 shares in the last quarter. Finally, Merit Financial Group LLC boosted its position in Thermo Fisher Scientific by 34.0% during the 4th quarter. Merit Financial Group LLC now owns 15,504 shares of the medical research company’s stock worth $8,984,000 after acquiring an additional 3,934 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $574.47, for a total value of $5,744,700.00. Following the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at $71,191,194.75. This trade represents a 7.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 5,850 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $580.00, for a total transaction of $3,393,000.00. Following the sale, the vice president directly owned 14,784 shares of the company’s stock, valued at approximately $8,574,720. This represents a 28.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 26,553 shares of company stock worth $15,343,589. 0.33% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Wolfe Research started coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 target price on the stock. Barclays lifted their target price on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Royal Bank Of Canada increased their price objective on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a report on Friday, July 24th. Evercore set a $570.00 price objective on Thermo Fisher Scientific in a research report on Monday, July 6th. Finally, Stifel Nicolaus set a $650.00 target price on Thermo Fisher Scientific in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $619.41.

Thermo Fisher Scientific Stock Down 0.3%

Thermo Fisher Scientific stock opened at $603.20 on Thursday. The company has a market capitalization of $223.03 billion, a P/E ratio of 32.45, a P/E/G ratio of 2.46 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $643.99. The firm’s fifty day simple moving average is $524.79 and its 200-day simple moving average is $509.23. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business’s revenue was up 10.5% compared to the same quarter last year. During the same period last year, the company earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.